Maffione A.M.,Head Service of Nuclear Medicine and Center |
Ferretti A.,Head Service of Nuclear Medicine and Center |
Chondrogiannis S.,Head Service of Nuclear Medicine and Center |
Rampin L.,Head Service of Nuclear Medicine and Center |
And 5 more authors.
Clinical Nuclear Medicine | Year: 2013
Purpose: The aim of this study was to correlate PERCIST criteria and a new criterion developed in our center that we named PREDIST (PET Residual Disease in Solid Tumor) with tumor regression grade (TRG) classification of pathologic response to neoadjuvant chemoradiotherapy (CRT) in patients affected by rectal cancer. Methods: Seventy-three consecutive patients affected by locally advanced rectal cancer (LARC) were retrospectively included. FDG-PET/CT scans were performed at staging time and after the end of CRT (mean time 6.5 weeks). The analysis was performed by PERCIST criteria 1.0 and PREDIST criteria based on a new definition of residual disease. We split the TRG system into responders (TRG1-2) and nonresponders (TRG3-5). Pearson chi-square analysis by cross-tabulations was performed. Results: PREDIST classification was statistically predictive of TRG response (P = 0.004, sensitivity 81.8%and specificity 54.9%). On the contrary, PERCIST criteria was not statistically correlated to TRG (P = 0.128) caused by a very low specificity (9.8%). Conclusions: FDG-PET/CT scan is an accurate tool to predict preoperatively the response to CRT in LARC patients. The novel proposed criterion (PREDIST) seems to be helpful to discriminate responder by nonresponder patients. Copyright © 2013 by Lippincott Williams & Wilkins.